Alveron pharma logo.png
  • HOME

  • COMPANY

    • HISTORY
    • TEAM
    • SUPERVISORY BOARD
    • SCIENTIFIC ADVISORY BOARD
    • INVESTORS
  • TECHNOLOGY

  • NEWS

  • CONTACT

  • More

    Use tab to navigate through the menu items.

    Alveron Pharma is developing a unique coagulation

    platform technology with the world's first

    cyclodextrin-based anticoagulant reversal drug 

    Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.

    Latest news
    Alveron Pharma BV raises a further EUR 3.9 million to progress first in class drug

    Alveron Pharma BV raises a further EUR 3.9 million to progress first in class drug

    Alveron pharma logo.png
     
    Contact us

    Alveron Pharma

    NovioTech Campus

    Transistorweg 5

    6534 AT Nijmegen

    The Netherlands

     

    ​

    Postal address:

    Gasstraat 20 

    Kantoor 2.16 

    5349 AA Oss

    The Netherlands

    ​

    info@alveron.com

    © 2021 Alveron Pharma, all rights reserved.  Design by Brightlands Maastricht Health Campus